Help Stop the Spread of Influenza

Give an early, accurate flu diagnosis

Influenza affects 5-10% of adults and 20-30% of children each year.1 Whether it’s a typical flu season, or a worst-case pandemic, testing and screening for influenza A and B can help protect patients.
Get the speed and reliability you need to support a timely, accurate diagnosis with the cobas® Influenza A/B Test.

Influenza A2

1

Influenza B2

2

The cobas® Liat® PCR System vs. Conventional methods

Multi-test algorithm


point-of-care-strep-test-influenza-test-multi-test-algorithm-image-vertical

cobas® Influenza A/B test


InfluenzaAB_cobas_InfluenzaAB


Intended use for cobas® Influenza A/B test2

The cobas® Influenza A/B nucleic acid test for use on the cobas® Liat® System is a multiplex real-time RT-PCR assay for the detection of Influenza A virus and Influenza B virus RNA in nasopharyngeal swab specimens from patients with signs and symptoms of respiratory infection in conjunction with clinical and epidemiological risk factors.
The test is intended for use as an aid in the differential diagnosis of Influenza A and Influenza B in humans and is not intended to detect Influenza C.
CE-IVD and FDA 510(k) cleared; CLIA waived. This product is not registered as an in vitro diagnostic (IVD) in all countries; additional information may be available from your Roche sales representative.

Learn more about the expanding menus of assays

CI=confidence intervals. LOD=limit of detection. TCID50= tissue culture infectious dose.
*Influenza A: Of 15 cobas® Liat® System positive, culture negative specimens, 9 were positive and 6 were negative by PCR/sequencing. Two cobas® Liat® System negative, culture positive specimens were positive by PCR/sequencing.
**Influenza B: Of 16 cobas® Liat® System positive, culture negative specimens, 14 were positive and 2 were negative by PCR/sequencing. One cobas® Liat® System negative, culture positive specimen was positive by PCR/sequencing and was negative by lab-based RT-PCR.
cobas® MRSA/SA results delivered in under 30 minutes.

References: 1. World Health Organization. Vaccines against influenza. WHO position paper – November 2012 Weekly Epidemiol Record. 2012;87(47):461–76. 2. cobas® Influenza A/B [package insert]. Pleasanton, CA: Roche Molecular Systems, Inc., 2015. 3. Centers for Disease Control and Prevention. Use of antivirals. http://www.cdc.gov/flu/professionals/antivirals/antiviral-use-influenza.htm. Accessed April 20, 2017.